brand logo

Am Fam Physician. 1998;58(5):1070

to the editor: In the article written by Drs. Cupp and Tracy1 on cytochrome P450 enzymes, the first illustrative case describes a patient who developed dry mouth, dizziness and prolongation of the prothrombin time after paroxetine and then fluoxetine were added to her medication regimen, which included amitriptyline and warfarin.

In Table 1, paroxetine is listed as an inhibitor and amitriptyline is listed as a substrate.1 Warfarin is listed as a substrate in Tables 3 and 41; however, neither of these tables lists paroxetine or fluoxetine as a potential inhibitor.

Presumably the patient's dry mouth and dizziness were related to a drug interaction between paroxetine and amitriptyline; however, what was the reason for the prolonged International Normalized Ratio (INR)?

in reply: We appreciate Dr. Liu's question concerning the cause of the prolonged International Normalized Ratio (INR) in the patient described in the illustrative case.A section of the text that would have explained this drug interaction was omitted from the final version of the manuscript at the suggestion of a reviewer who thought it would be “confusing to clinicians.” However, we feel, as does Dr. Liu, that this interaction warrants an explanation.

Warfarin is a racemic mixture of R-warfarin and S-warfarin, which differ in potency and metabolic pathways.1 R-warfarin is a less potent anticoagulant than is S-warfarin,1 which is metabolized by CYP2C9.2 CYP1A2 and CYP3A are the enzymes responsible for the metabolism of the less potent R-warfarin.

In the case presented in our article, the addition of fluoxetine, a CYP3A inhibitor, to the medication regimen of the patient was the likely cause of the increase in the INR. There is also limited information that suggests fluoxetine is a CYP2C9 inhibitor3; thus, it is an inhibitor of the more potent S-enantmer.

Despite case reports of a drug interaction between fluoxetine and warfarin,4 results of a pharmacokinetic study5 did not support a clinically significant interaction. Physicians may or may not see a change in the INR of a patient when a CYP3A inhibitor is added to warfarin therapy. The propensity for a clinically significant interaction might be influenced by interindividual activity of CYP3A, or by other medications taken by the patient that inhibit other warfarin metabolic pathways.

Email letter submissions to afplet@aafp.org. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors. Letters submitted for publication in AFP must not be submitted to any other publication. Letters may be edited to meet style and space requirements.

This series is coordinated by Kenny Lin, MD, MPH, deputy editor.

Continue Reading


More in AFP

Copyright © 1998 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See https://www.aafp.org/about/this-site/permissions.html for copyright questions and/or permission requests.